In-depth case study webinar: how MolMed achieved large-scale GMP production of LV and RV Vectors

Case study: MolMed presents process development and large-scale GMP production for lentiviral (LV) and retroviral (RV) vectors in the iCELLis® 500 fixed-bed bioreactor

MolMed is a biotechnology company focused on research, development and manufacturing of innovative therapies to treat cancer and rare genetic diseases. MolMed has developed a robust and scalable process for the industrial scale production of both LV and RV vectors for use in gene-modified cell therapy using the iCELLis bioreactor platforms.

Molmed present the development and optimization of their LV and RV vector production processes in the scale down iCELLis nano bioreactor. The processes were then scaled up to the production scale iCELLis 500 bioreactor and results were comparable to processes performed at small scale.

Webinar participants learn:

• How an iCELLis bioreactor can used for commercial scale vector production
• MolMed’s process development and large-scale production process using the iCELLis platform
• How to develop industrial scale viral vector production

[#speakersPlaceHolder]

Giuliana Vallanti

Director, Development & Quality Control at MolMed SpA

Giuliana Vallanti is Development and Quality Control Director and Qualified Person at MolMed. She joined MolMed in 2005 and worked with growing responsibilities in Development and Quality Control units, contributing to the development of processes and assays in cell and gene therapy field.

She has main experiences in the development and industrialization of T- and haematopietic cells transduction processes with lentiviral and retroviral vectors. She worked on the development of GMP processes for large scale vectors production and purification.She holds a degree in Biology from Università degli Studi – Urbino and a Ph.D. in biochemical and pharmacological methods with a study on Lentiviral Vector for gene therapy anti HIV-1.

Clive Glover

Director, Strategy at Pall Biotech

Dr Clive Glover is the Director, Strategy at Pall Biotech where he leads Pall’s cell and gene therapy business. Previously he was responsible for driving product development efforts around cell therapy at GE Healthcare and has also held positions in marketing and product management at STEMCELL Technologies. Clive holds a PhD in Genetics from the University of British Columbia.

Watch now

SPEAKERS

Giuliana Vallanti

Director, Development & Quality Control at MolMed SpA

Clive Glover

Director, Strategy at Pall Biotech

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 70

Days

Register

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe

29 May

in 41

Days

Register

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

in 35

Days

Register

T cells from beginning to end: optimizing leukopak and drug product cryopreservation

Meredith Safford, ShaNelle Yelity

22 May

in 34

Days

Register

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes

21 May

in 33

Days

Register